This Article Full Text Full Text (PDF) All Versions of this Article: 52/6/994    most recent HYPERTENSIONAHA.108.117689v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Smajilovic, S. Articles by Tfelt-Hansen, J. Search for Related Content PubMed PubMed Citation Articles by Smajilovic, S. Articles by Tfelt-Hansen, J. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Animal models of human disease Other hypertension Receptor pharmacology Other Vascular biology

(Hypertension. 2008;52:994.)
© 2008 American Heart Association, Inc.

Brief Reviews

Novel Role of the Calcium-Sensing Receptor in Blood Pressure Modulation

From the Laboratory of Molecular Cardiology (S.S., J.T-H.), Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark; and the Danish National Research Foundation Centre for Cardiac Arrhythmia (S.S., J.T-H.), Copenhagen, Denmark.

Correspondence to Jacob Tfelt-Hansen, Laboratory of Molecular Cardiology, Department of Cardiology, Section 9312, Copenhagen University Hospital, Rigshospitalet, Juliane Mariesvej 20, DK 2100 Copenhagen O, Denmark. E-mail tfelt@dadlnet.dk

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The calcium-sensing receptor (CaR) was cloned in 1993 from bovine parathyroid gland.¹ Subsequently, the receptor was reported in a wide range of tissues and cell types. It belongs to the superfamily C of the G protein–coupled receptors, which are also known as 7 transmembrane receptors.

The CaR is a promiscuous receptor that, in addition to extracellular calcium (Ca²⁺o), recognizes many other ligands.² CaR ligands are divided into type I agonists, which are direct agonists, and type II, which act as allosteric modulators that change the affinity of the receptor to calcium and other cations. The newly developed calcimimetics are type II agonists that bind to the transmembrane domain and positively modulate the CaR.³ These drugs have been introduced recently in the treatment of uremic secondary hyperparathyroidism.⁴

The binding of Ca²⁺o or other CaR agonists to the CaR elicits complex intracellular signals through modulation by the CaR of a wide array of intracellular signaling proteins, including G proteins and phospholipase C, which stimulates inositol triphosphate production. Downstream of or in parallel with phospholipase C, the CaR also activates mitogen-activated protein kinases (MAPKs).

The most important physiological function of the CaR is to maintain and regulate systemic calcium homeostasis. In parathyroid glands, the CaR inhibits secretion of parathyroid hormone (PTH), the key calcium-regulating hormone. The CaR is also expressed in bone, kidney, and intestine, the major calcium-translocating organs. In the kidney, the receptor regulates renal sodium and ion transport, although the exact mechanisms of action are not fully established.

. . . [Full Text of this Article]